347 related articles for article (PubMed ID: 15985112)
1. Predictors of a negative response to topiramate therapy in patients with chronic migraine.
Rothrock JF; Parada VA; Drinkard R; Zweifler RM; Key KF
Headache; 2005; 45(7):932-5. PubMed ID: 15985112
[TBL] [Abstract][Full Text] [Related]
2. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
[TBL] [Abstract][Full Text] [Related]
4. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study.
Krymchantowski AV; Jevoux CC
Headache; 2011 Apr; 51(4):554-8. PubMed ID: 21457240
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study.
Shaygannejad V; Janghorbani M; Ghorbani A; Ashtary F; Zakizade N; Nasr V
Headache; 2006 Apr; 46(4):642-8. PubMed ID: 16643559
[TBL] [Abstract][Full Text] [Related]
6. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study.
Lipton RB; Silberstein S; Dodick D; Cady R; Freitag F; Mathew N; Biondi DM; Ascher S; Olson WH; Hulihan J
Cephalalgia; 2011 Jan; 31(1):18-30. PubMed ID: 20974598
[TBL] [Abstract][Full Text] [Related]
7. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
[TBL] [Abstract][Full Text] [Related]
8. Long-term migraine prevention with topiramate: open-label extension of pivotal trials.
Rapoport A; Mauskop A; Diener HC; Schwalen S; Pfeil J
Headache; 2006; 46(7):1151-60. PubMed ID: 16866719
[TBL] [Abstract][Full Text] [Related]
9. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.
Yaldo AZ; Wertz DA; Rupnow MF; Quimbo RM
Clin Ther; 2008 Dec; 30(12):2452-60. PubMed ID: 19167603
[TBL] [Abstract][Full Text] [Related]
10. Topiramate in migraine prevention: results of a large controlled trial.
Silberstein SD; Neto W; Schmitt J; Jacobs D;
Arch Neurol; 2004 Apr; 61(4):490-5. PubMed ID: 15096395
[TBL] [Abstract][Full Text] [Related]
11. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
[TBL] [Abstract][Full Text] [Related]
12. The impact of migraine on daily activities: effect of topiramate compared with placebo.
Silberstein SD; Loder E; Forde G; Papadopoulos G; Fairclough D; Greenberg S
Curr Med Res Opin; 2006 Jun; 22(6):1021-9. PubMed ID: 16846536
[TBL] [Abstract][Full Text] [Related]
13. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study).
Gupta P; Singh S; Goyal V; Shukla G; Behari M
Headache; 2007 Mar; 47(3):402-12. PubMed ID: 17371357
[TBL] [Abstract][Full Text] [Related]
14. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial.
Winner P; Pearlman EM; Linder SL; Jordan DM; Fisher AC; Hulihan J;
Headache; 2005; 45(10):1304-12. PubMed ID: 16324162
[TBL] [Abstract][Full Text] [Related]
15. Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications.
Cady RK; Voirin J; Farmer K; Browning R; Beach ME; Tarrasch J
Headache; 2012 May; 52(5):749-64. PubMed ID: 22188311
[TBL] [Abstract][Full Text] [Related]
16. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.
Diener HC; Agosti R; Allais G; Bergmans P; Bussone G; Davies B; Ertas M; Lanteri-Minet M; Reuter U; Sánchez Del Río M; Schoenen J; Schwalen S; van Oene J;
Lancet Neurol; 2007 Dec; 6(12):1054-62. PubMed ID: 17988947
[TBL] [Abstract][Full Text] [Related]
17. Antiepileptic drugs in migraine prevention.
Mathew NT
Headache; 2001; 41 Suppl 1():S18-24. PubMed ID: 11903536
[TBL] [Abstract][Full Text] [Related]
18. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache.
Limmroth V; Biondi D; Pfeil J; Schwalen S
Headache; 2007 Jan; 47(1):13-21. PubMed ID: 17355489
[TBL] [Abstract][Full Text] [Related]
19. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety.
Winner P; Gendolla A; Stayer C; Wang S; Yuen E; Battisti WP; Nye JS
Headache; 2006; 46(10):1503-10. PubMed ID: 17115983
[TBL] [Abstract][Full Text] [Related]
20. The impact of topiramate on health-related quality of life indicators in chronic migraine.
Dodick DW; Silberstein S; Saper J; Freitag FG; Cady RK; Rapoport AM; Mathew NT; Hulihan J; Crivera C; Rupnow MF; Mao L; Finlayson G; Greenberg SJ
Headache; 2007; 47(10):1398-408. PubMed ID: 18052949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
